Treatment of Graves’ disease in patients with thyroid eye disease

Close metadata

Recommended articles:

Bony orbital decompression in thyroid eye disease. Russian Annals of Ophthalmology. 2024;(1):103-108

Dacryocystorhinostomy with a counteropening in the treatment of secondary nasolacrimal duct obstruction after radioiodine therapy. Russian Annals of Ophthalmology. 2024;(2-2):60-67

Glucocorticoid-resistant forms of endocrine ophthalmopathy. Russian Annals of Ophthalmology. 2024;(6):125-130

First experience of applying domestic video fluorescent equipment for visualization and blood flow evaluation of the parathyroid glands. Pirogov Russian Journal of Surgery. 2024;(1):71-78

Simultaneous thyroidectomy for follicular adenocarcinoma and subclavian-carotid prosthetics. P.A. Herzen Journal of Oncology. 2024;(5):59-61

Graves’ disease (GD) is an autoimmune disease that is often complicated by thyroid eye disease (TED). Clinical presentations of TED can develop simultaneously with the manifestation of GD, after the manifestation of GD amid treatment, and before the development of thyrotoxicosis. Treatment of such patients is a difficult task, because on the one hand, it is necessary to take into account the clinical picture of thyrotoxicosis, and on the other — the symptoms of eye damage. The combination of the two pathologies determines the need for simultaneous treatment of GD and TED, and the choice of a treatment method for GD will depend on the manifestations of TED. This article presents current views on the treatment of GD with concomitant TED. The choice of GD treatment method will be largely determined by the clinical manifestations of TED and will be conducted jointly by endocrinologists and ophthalmologists.

Keywords:

Graves’ disease

thyroid eye disease

radioiodine therapy

thyroidectomy

Authors:

Sviridenko N.Yu.

National Medical Research Center for Endocrinology

ORCID: 0000-0002-8538-5354

Sheremeta M.S.

Scientific Medical Research Center of Endocrinology

Belovalova I.M.

Scientific Medical Research Center of Endocrinology

Melnichenko G.A.

National Medical Center of Endocrinology

Received:

05.06.2021

Accepted:

29.09.2021

List of references:

Kahaly GJ, Bartalena L, Hegedus L, et al. European Thyroid Association Guideline for the management of Graves Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186. https://doi.org/10.1159/000490384
Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy. Front Endocrinol. 2020;11:913. https://doi.org/10.3389/fendo.2020.615993
Bartallena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: Reality and Perspectives. Endocrine Rev. 2000;21(2):168-199. https://doi.org/10.1210/edrv.21.2.0393
Autoimmunnaya patologiya shchitovidnoy zhelezy i endokrinnaya oftal’mopatiya [Autoimmune pathology of the thyroid gland and endocrine ophthalmopathy]. Eds Dedov II, Melnichenko GA. Moscow: Izdatel’stvo Printing affairs master; 2020 (In Russ.).
Brovkina AF. Endocrinnaya ofthal’mopatiya. [Endocrine ophthalmopathy]. M.: GEOTAR-Media; 2008. (In Russ.).
Russian Association of Endocrinologists. Natsional’nyye rekomendatsii: Tireotoksikoz s diffuznym zobom (diffuznyy toksicheskiy zob, bolezn’ Greyvsa—Bazedova), uzlovym/mnogouzlovym zobom [National recommendations: Thyrotoxicosis with diffuse goiter (diffuse toxic goiter, Graves-Bazedov disease), nodular/multi-nodular goiter]. M. 2014. (In Russ.).
Sviridenko NYu, Likhantseva VG, Belovalova IM, et al. Anti-TSH receptor antibodies as predictors of the severity and outcome of endocrine ophthalmopathy in the patients presenting with Graves’ disease. Problemy endokrinologii = Problems of Endocrinology. 2011;57(2):23-26. (In Russ.). https://doi.org/10.14341/probl201157223-26
Diana T, Krause J, Olivo PD, et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189:304-309. https://doi.org/10.1111/cei.12980
Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. Saudi J Ophthalmol. 2011;25(1):3-13. https://doi.org/10.1016/j.sjopt.2010.10.001
Rapoport B, McLachlan SM. TSH receptor cleavage into subunits and shedding of the Asubunit; a molecular and clinical perspective. Endocr Rev. 2016;37:114-134. https://doi.org/10.1210/er.2015-1098
Wall JR, Lahooti H. Pathogenesis of thyroid eye disease — does autoimmunity against the TSH receptor explain all cases? Endokrynol Pol. 2010;61(2): 222-227.
Diana T, Wüster C, Olivo PD, et al. Performance and Specificity of 6 Immunoassays for TSH Receptor Antibodies: A Multicenter Study. Eur Thyroid J. 2017;6(5):243-249. https://doi.org/10.1159/000478522
Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J 2016;5:9-26. https://doi.org/10.1159/000443828
Ross DS. Radioiodine Treatment in Patients with Graves’ Disease. In: Graves’ Disease. Vol 6. New York, NY: Springer New York; 2015;83-98. https://doi.org/10.1007/978-1-4939-2534-6_7
Rumyantsev PO, Sheremeta MS, Sviridenko NYu, Trukhin AA. Therapy with radioactive iodine. In: Endokrinologiya. Natsional’noye rukovodstvo [Endocrinology. National guideline]. Eds Dedova II, Melnichenko GA. M.: GEOTAR-Media; 2020. (In Russ.).
Acharya SH, Avenell A, Philip S, et al. Radioiodine therapy (RAI) for Graves’disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf). 2008;69(6):943-950. https://doi.org/10.1111/j1365-2265.2008.03279.x
Pinchera A, Bartalena L, Marcocci C. Therapeutic controversies. Radioiodine may be bad for Graves’ ophthalmopathy, but… J Clin Endocrinol Metab. 1995;80:342-345. https://doi.org/10.1210/jcem. 80.2.7852486
Aizawa Y, Yoshida K, Kaise N, et al. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves’ disease. Clin. Endocrinol. 1995; 4:517-522. https://doi.org/10.1111/j.1365-2265.1995.tb02671.x
Dreval AV, Tsyb AF, Nechaeva OA, et al. Effects of Radioiodine Therapy on the Natural History of Graves’ Ophtalmopathy. Klinicheskaya i eksperimental’naya tireoidologiya = Clinical and experimental thyroidology. 2007;3(3): 33-40 (In Russ.). https://doi.org/10.14341/ket20073333-40
Vestergaard P. Smoking and thyroid disorders — a meta-analysis. Eur J Endocrinol. 2002;146(2):153-161. https://doi.org/10.1530/eje.0.1460153
Plazinska MT, Sawicka-Gutaj N, Czarnywojtek A, et al. Radioiodine therapy and Graves’ disease — Myths and reality. PLoS ONE. 2020;15(1): e0226495. https://doi.org/10.1371/journal.pone.0226495
Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20(7):777-783. https://doi.org/10.1089/thy.2010.1634
Khong JJ, Finch S, De Silva C, et al. Risk factors for Graves’ orbitopathy; the Australian Thyroid-Associated Orbitopathy (ATOR) study. J Clin Endocrinol Metab. 2016;101(7):2716-2720. https://doi.org/10.1210/jc.2015-4294
Jorde R, Sundsfjord J. Serum TSH levels in smoking and non-smoking patients. The 5th Tromsø study. Exp Clin Endocrinol Diabetes. 2006;114:343-347. https://doi.org/10.1055/s-2006-924264
Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92(1):59-64. https://doi.org/10.1210/jc.2006-1824
Quadbeck B, Roggenbuck U, Janssen OE, et al. Impact of smoking on the course of Graves’ disease after withdrawal of antithyroid drugs. Exp Clin Endocrinol Diabetes. 2006;114:406-411. https://doi.org/10.1055/s-2006-924065
Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med. 1992;326:1733-1738. https://doi.org/10.1056/NEJM199206253262603
Sisson JC, Schipper MJ, Nelson CC, et al. Therapy and Graves’ Ophthalmopathy. J Nuclear Medicine. 2008;49(6):923-930. https://doi.org/10.2967/jnumed.107.049437
Eckstein A, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metabol. 2006;91(9): 3464-3470. https://doi.org/10.1210/jc.2005-2813
Lantz M, Planck T, Asman P, Hallengren B. Increased TRAb and/or Low Anti-TPO Titers at Diagnosis of Graves’ Disease are Associated with an Increased Risk of Developing Ophthalmopathy after Onset. Exp Clin Endocrinol Diabetes. 2014;122:113-117. https://doi.org/10.1055/s-0033-1363193
Eckstein AK, Plicht M, Lax H, et al. Clinical results of anti-inflammatory therapy in Graves ophthalmopathy and association with thyroidal autoantibodies. Clin Endocrinol Oxf. 2004;61:612-618. https://doi.org/10.1111/j.1365-22654.2004.02143.x
Mancini A, Segni C, Raimondo S, et al. Thyroid Hormones, Oxidative Stress and Inflammation. Mediat Inflamm. 2016;1:1-12. https://doi.org/10.1155/2016/6757154
Perros, P, Kendall-Taylor P, Neoh C, et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves’ ophthalmopathy. J Clin Endocrinol Metabol. 2005;90(9):5321-5323. https://doi.org/10.1210/jc.2005-0507
Vannucchi G, Covelli D, Campi I, et al. Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves’ disease patients undergoing radioiodine ablation: A prospective randomized control trial study. Thyroid. 2019;29(12):1828-1833. https://doi.org/10.1089/thy.2019.0150
Ross DS, Burch HB, Cooper DS, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421. https://doi.org/10.1089/thy.2016.0229
Sviridenko N, Sheremeta M, Grusha Y. International Symposium for Thyroid Eye Disease (June 2016, London). Clin Exper Thyroidol. 2017;12(3):12-19. https://doi.org/10.14341/ket2016312-19
Jensen BE, Bonnema SJ, Hegedus L. Glucocorticoids do not influence the effect of radioiodine therapy in Graves’ disease. Eur J Endocrinol. 2005; 153(1):15-21. https://doi.org/10.1530/eje.1.01938
Guo Z, Yu P, Liu Z, et al. Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ diseases: a meta-analysis of randomized clinical trials. Clin Endocrinol. 2013;79(5):739-746. https://doi.org/10.1111/cen.12209
Opoku-Boateng A, Wang TS, Sosa JA. Thyroidectomy in Patients with Graves’ Disease. In: Graves’ Disease. Vol 17. New York, NY: Springer New York; 2015. https://doi.org/10.1007/978-1-4939-2534-6_8
Bartalena L, Macchia PE, Marcocci C, et al. Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest. 2015; 38(4):481-487. https://doi.org/10.1007/s40618-015-0257-z
Marcocci C, Kahaly GJ, Krassas GE, et al. European Group on Graves Orbitopathy: Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920-1931. https://doi.org/10.1056/NEJMoa101298
Bartalena L. The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab. 2011;96(3):592-599. https://doi.org/10.1210/jc.2010-2329
Laurberg P, Berman DC, Andersen S, et al. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21(9):951-956. https://doi.org/10.1089/thy.2011.0039
Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid. 2011;21(3):279-283. https://doi.org/10.1089/thy.2010.0181
Ismailova DS, Belovalova IM, Grusha YO, Sviridenko NS. Orbital decompression in the system of treatment for complicated thyroid eye disease: case report and literature review. Int Med Case Rep J. 2018;11:243-249. https://doi.org/10.2147/IMCRJ.S164372

Close metadata